This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ito, S. Articles by Takahashi, M. Search for Related Content PubMed PubMed Citation Articles by Ito, S. Articles by Takahashi, M.

Biological Properties of Ret with Cysteine Mutations Correlate with Multiple Endocrine Neoplasia Type 2A, Familial Medullary Thyroid Carcinoma, and Hirschsprung's Disease Phenotype¹

Departments of Pathology [S. I., T. I., N. A., H. M., Y. I., M. T.] and Neurology [S. I., G. S.], Nagoya University School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466, Japan

We investigated the transforming activity of the ret proto-oncogene with a mutation in cysteine 609, 611, 618, 620, 630, or 634 detected in patients with multiple endocrine neoplasia type 2A (MEN 2A), familial medullary thyroid carcinoma (FMTC), or Hirschsprung's disease. Of these cysteine mutations, codon 634 mutations are known to be correlated with the development of MEN 2A, whereas codon 609, 618, or 620 mutations were detected in two-thirds of FMTCs and in several cases of Hirschsprung's disease. Analysis of a total of 18 mutant genes revealed that codon 634 mutations have the highest transforming activity. The activity of ret with a codon 609, 611, 618, or 620 mutation and with a codon 630 mutation was approximately 3- to 5-fold and 2-fold lower than that of ret with a codon 634 mutation, respectively. In addition, different amino acid substitutions for the same cysteine displayed comparable transforming activity. The expression of the cell surface form of Ret with codon 609, 611, 618, or 620 mutation was very low compared with that of Ret with codon 634 mutation, indicating that the former four mutations might impair transport of Ret to the plasma membrane, as observed for several Hirschsprung mutations affecting the Ret extracellular domain. These results thus suggest that mutations in cysteine 609, 611, 618, or 620 may have the potential to develop Hirschsprung's disease in addition to MEN 2A and FMTC.

¹ This work was supported in part by grants-in-aid for scientific research and for cancer research from the Ministry of Education, Science and Culture of Japan.

² The first two authors contributed equally to this work.

³ To whom requests for reprints should be addressed. Phone: 52-744-2092; Fax: 52-744-2098.

Received 4/14/97. Accepted 6/10/97.

This article has been cited by other articles:

				J. W. B. de Groot, T. P. Links, J. T. M. Plukker, C. J. M. Lips, and R. M. W. Hofstra RET as a Diagnostic and Therapeutic Target in Sporadic and Hereditary Endocrine Tumors Endocr. Rev., August 1, 2006; 27(5): 535 - 560. [Abstract] [Full Text] [PDF]

				C. Carniti, S. Belluco, E. Riccardi, A. N. Cranston, P. Mondellini, B. A.J. Ponder, E. Scanziani, M. A. Pierotti, and I. Bongarzone The RetC620R Mutation Affects Renal and Enteric Development in a Mouse Model of Hirschsprung's Disease Am. J. Pathol., April 1, 2006; 168(4): 1262 - 1275. [Abstract] [Full Text] [PDF]

				A. Machens, M. Brauckhoff, H.-J. Holzhausen, P. N. Thanh, H. Lehnert, and H. Dralle Codon-Specific Development of Pheochromocytoma in Multiple Endocrine Neoplasia Type 2 J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 3999 - 4003. [Abstract] [Full Text] [PDF]

				M. Jijiwa, T. Fukuda, K. Kawai, A. Nakamura, K. Kurokawa, Y. Murakumo, M. Ichihara, and M. Takahashi A Targeting Mutation of Tyrosine 1062 in Ret Causes a Marked Decrease of Enteric Neurons and Renal Hypoplasia Mol. Cell. Biol., September 15, 2004; 24(18): 8026 - 8036. [Abstract] [Full Text] [PDF]

				R. M. Melillo, A. M. Cirafici, V. De Falco, M. Bellantoni, G. Chiappetta, A. Fusco, F. Carlomagno, A. Picascia, D. Tramontano, G. Tallini, et al. The Oncogenic Activity of RET Point Mutants for Follicular Thyroid Cells May Account for the Occurrence of Papillary Thyroid Carcinoma in Patients Affected by Familial Medullary Thyroid Carcinoma Am. J. Pathol., August 1, 2004; 165(2): 511 - 521. [Abstract] [Full Text] [PDF]

				G. Cuccuru, C. Lanzi, G. Cassinelli, G. Pratesi, M. Tortoreto, G. Petrangolini, E. Seregni, A. Martinetti, D. Laccabue, C. Zanchi, et al. Cellular Effects and Antitumor Activity of RET Inhibitor RPI-1 on MEN2A-Associated Medullary Thyroid Carcinoma J Natl Cancer Inst, July 7, 2004; 96(13): 1006 - 1014. [Abstract] [Full Text] [PDF]

				E. Arighi, A. Popsueva, D. Degl'Innocenti, M. G. Borrello, C. Carniti, N. M. Perala, M. A. Pierotti, and H. Sariola Biological Effects of the Dual Phenotypic Janus Mutation of ret Cosegregating with Both Multiple Endocrine Neoplasia Type 2 and Hirschsprung's Disease Mol. Endocrinol., April 1, 2004; 18(4): 1004 - 1017. [Abstract] [Full Text] [PDF]

				A. Machens, P. Niccoli-Sire, J. Hoegel, K. Frank-Raue, T. J. van Vroonhoven, H.-D. Roeher, R. A. Wahl, P. Lamesch, F. Raue, B. Conte-Devolx, et al. Early Malignant Progression of Hereditary Medullary Thyroid Cancer N. Engl. J. Med., October 16, 2003; 349(16): 1517 - 1525. [Abstract] [Full Text] [PDF]

				G. Szinnai, C. Meier, P. Komminoth, and U. W. Zumsteg Review of Multiple Endocrine Neoplasia Type 2A in Children: Therapeutic Results of Early Thyroidectomy and Prognostic Value of Codon Analysis Pediatrics, February 1, 2003; 111(2): e132 - 139. [Abstract] [Full Text] [PDF]

				B. Mograbi, R. Bocciardi, I. Bourget, T. Juhel, D. Farahi-Far, G. Romeo, I. Ceccherini, and B. Rossi The Sensitivity of Activated Cys Ret Mutants to Glial Cell Line-Derived Neurotrophic Factor Is Mandatory To Rescue Neuroectodermic Cells from Apoptosis Mol. Cell. Biol., October 15, 2001; 21(20): 6719 - 6730. [Abstract] [Full Text] [PDF]

				A. Machens, O. Gimm, R. Hinze, W. Höppner, B. O. Boehm, and H. Dralle Genotype-Phenotype Correlations in Hereditary Medullary Thyroid Carcinoma: Oncological Features and Biochemical Properties J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1104 - 1109. [Abstract] [Full Text]

				J. R Hansford and L. M Mulligan Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis J. Med. Genet., November 1, 2000; 37(11): 817 - 827. [Abstract] [Full Text]

				K. Kawai, T. Iwashita, H. Murakami, N. Hiraiwa, A. Yoshiki, M. Kusakabe, K. Ono, K.-i. Iida, A. Nakayama, and M. Takahashi Tissue-specific Carcinogenesis in Transgenic Mice Expressing the RET Proto-Oncogene with a Multiple Endocrine Neoplasia Type 2A Mutation Cancer Res., September 1, 2000; 60(18): 5254 - 5260. [Abstract] [Full Text]

				Y. Ishiguro, T. Iwashita, H. Murakami, N. Asai, K.-i. Iida, H. Goto, T. Hayakawa, and M. Takahashi The Role of Amino Acids Surrounding Tyrosine 1062 in Ret in Specific Binding of the Shc Phosphotyrosine-Binding Domain Endocrinology, September 1, 1999; 140(9): 3992 - 3998. [Abstract] [Full Text]

				P. Pigny, C. Bauters, J.-L. Wemeau, M. Lecomte Houcke, M. Crepin, P. Caron, S. Giraud, A. Calender, M.-P. Buisine, J.-P. Kerckaert, et al. A Novel 9-Base Pair Duplication in RET Exon 8 in Familial Medullary Thyroid Carcinoma J. Clin. Endocrinol. Metab., May 1, 1999; 84(5): 1700 - 1704. [Abstract] [Full Text]

				S. M Myers, R. Salomon, A. Goessling, A. Pelet, C. Eng, A. von Deimling, S. Lyonnet, and L. M Mulligan Investigation of germline GFRalpha -1 mutations in Hirschsprung disease J. Med. Genet., March 1, 1999; 36(3): 217 - 220. [Abstract] [Full Text]

				C. Eng RET Proto-Oncogene in the Development of Human Cancer J. Clin. Oncol., January 1, 1999; 17(1): 380 - 380. [Abstract] [Full Text] [PDF]

				R H Sijmons, R M W Hofstra, F A Wijburg, T P Links, R P Zwierstra, A Vermey, D C Aronson, G Tan-Sindhunata, G J Brouwers-Smalbraak, S M Maas, et al. Oncological implications of RET gene mutations in Hirschsprung's disease Gut, October 1, 1998; 43(4): 542 - 547. [Abstract] [Full Text] [PDF]

				S. Borrego, C. Eng, B. Sánchez, M.-E. Sáez, E. Navarro, and G. Antiñolo Molecular Analysis of the ret and GDNF Genes in a Family with Multiple Endocrine Neoplasia Type 2A and Hirschsprung Disease J. Clin. Endocrinol. Metab., September 1, 1998; 83(9): 3361 - 3364. [Abstract] [Full Text]

				F. Carlomagno, R. M. Melillo, R. Visconti, G. Salvatore, G. De Vita, G. Lupoli, Y. Yu, S. Jing, G. Vecchio, A. Fusco, et al. Glial Cell Line-Derived Neurotrophic Factor Differentially Stimulates Ret Mutants Associated with the Multiple Endocrine Neoplasia Type 2 Syndromes and Hirschsprung's Disease Endocrinology, August 1, 1998; 139(8): 3613 - 3619. [Abstract] [Full Text] [PDF]